Organisation paid for research Program year 2025 Source: CMS Open Payments

Aards Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,257,105

284 payments

Through program year 2025, Aards Research Inc is reported as receiving $1,257,105 in research payments, across 284 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$23,376	11
2024	Research	$26,601	11
2023	Research	$68,938	13
2022	Research	$102,844	73
2021	Research	$342,368	61
2020	Research	$324,917	53
2019	Research	$368,061	62

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $593,760 129 payments
GlaxoSmithKline, LLC. $368,371 99 payments
Gilead Sciences, Inc. $90,627 21 payments
Regeneron Pharmaceuticals, Inc. $71,192 15 payments
Eli Lilly and Company $56,260 4 payments
AstraZeneca UK Limited $45,864 7 payments
Pfizer Inc. $13,688 3 payments
Amgen Inc. $9,361 1 payment
Sanofi US Services Inc. $4,325 3 payments
Ablynx NV $3,656 2 payments

Studies the money was for Research payments · program years 2019–2025

A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $152,119 50 payments
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, $140,726 13 payments
M15-554 $137,334 16 payments
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $95,639 11 payments
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $74,554 28 payments
A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $71,192 15 payments
M19-944 $66,904 8 payments
A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $51,204 33 payments
M19-130 $43,976 4 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period $41,496 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.